Published in Eur Urol on April 16, 2011
Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int J Mol Sci (2012) 1.21
DNA methylation-based biomarkers in bladder cancer. Nat Rev Urol (2013) 1.05
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now? Adv Urol (2012) 0.91
Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev (2014) 0.89
High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res (2014) 0.85
Genetic and Epigenetic Alterations in Bladder Cancer. Int Neurourol J (2016) 0.83
The emerging role of GATA transcription factors in development and disease. Expert Rev Mol Med (2016) 0.79
Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview. Chin J Cancer Res (2016) 0.79
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer? Investig Clin Urol (2016) 0.76
Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer. Transl Oncol (2017) 0.75
Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention. Oncol Rev (2016) 0.75
Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis. BMC Urol (2016) 0.75
Prediction of Bacillus Calmette-Guerin Response in Patients with Bladder Cancer after Transurethral Resection of Bladder Tumor by Using Genetic Variation Based on Genomic Studies. Biomed Res Int (2016) 0.75
Bladder cancer: Predicting response to BCG. Nat Rev Urol (2011) 0.75
Analysis of bladder cancer tumor CpG methylation and gene expression within The Cancer Genome Atlas identifies GRIA1 as a prognostic biomarker for basal-like bladder cancer. Am J Cancer Res (2017) 0.75
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol (2013) 2.93
Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res (2010) 2.23
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Molecular lymph node staging in bladder urothelial carcinoma: impact on survival. Eur Urol (2008) 2.04
Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol (2010) 1.99
RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest (2012) 1.92
Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol (2010) 1.86
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Laparoscopic kidney transplantation. Eur Urol (2009) 1.68
Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin. Eur Urol (2008) 1.65
Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.63
DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol (2009) 1.59
Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy. Eur Urol (2007) 1.55
Genetic predisposition to early recurrence in clinically localized prostate cancer. BJU Int (2012) 1.50
Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology (2009) 1.47
Can we identify those patients who will benefit from prostate-sparing surgery? Predictive factors for invasive prostatic involvement by transitional cell carcinoma. Can J Urol (2011) 1.44
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol (2011) 1.39
Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med (2010) 1.34
Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int (2011) 1.23
Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol (2006) 1.14
Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res (2010) 1.14
Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics (2011) 1.14
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int (2006) 1.12
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol (2010) 1.12
Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg (2005) 1.10
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol (2006) 1.06
Prognostic factors in penile cancer. Urology (2010) 1.05
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol (2012) 1.04
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol (2012) 1.03
Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res (2007) 1.03
Conservative surgical therapy for leydig cell tumor. J Urol (2007) 1.02
Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol (2010) 1.01
Primary congenital bladder diverticula in children. Urology (2007) 0.98
Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol (2004) 0.98
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment. World J Urol (2012) 0.97
Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest (2013) 0.97
Differential protein expression profiling by iTRAQ-two-dimensional LC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene. Mol Cell Proteomics (2010) 0.96
Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res (2013) 0.94
Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry metabolomics approach. J Chromatogr A (2013) 0.93
Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol (2005) 0.92
Molecular mechanisms of the effects of olive oil and other dietary lipids on cancer. Mol Nutr Food Res (2007) 0.92
Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population. World J Urol (2014) 0.92
Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn (2010) 0.91
Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol (2012) 0.90
The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol (2010) 0.90
KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. Am J Pathol (2011) 0.89
Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. Cancer Genet Cytogenet (2007) 0.89
A re-adjustable sling for female recurrent stress incontinence and sphincteric deficiency: Outcomes and complications in 125 patients using the Remeex sling system. Neurourol Urodyn (2010) 0.88
Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol (2010) 0.87
Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology (2011) 0.86
Hemangioma of the prostatic urethra: holmium laser treatment. Urol Int (2008) 0.86
Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch (2010) 0.85
Prepubertal testicular tumours and efficacy of testicular preserving surgery. BJU Int (2010) 0.85
Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma. Eur Urol (2010) 0.84
Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J Proteome Res (2010) 0.84
Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010. BJU Int (2012) 0.84
Primary obstructive megaureter: initial experience with endoscopic dilatation. J Endourol (2007) 0.83
[Practical guideline for the management of adverse events associated with BCG installations]. Arch Esp Urol (2008) 0.83
Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. J Transl Med (2013) 0.83
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int (2008) 0.83
Detrusor quantitative morphometry in obstructed males and controls. J Urol (2006) 0.83
Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node metastasis of D1 (pT2-3pN1M0) prostate cancer. BJU Int (2004) 0.82
[Bilateral laparoscopic nephrectomy for renal cancer]. Arch Esp Urol (2004) 0.82
Efficiency of endoscopic treatment for vesico-ureteric reflux in adults. BJU Int (2008) 0.82
A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. PLoS One (2013) 0.82
Embolization of a bleeding aneurysm in a patient with spontaneous perirenal haematoma due to Polyarteritis nodosa. Arch Esp Urol (2005) 0.81
Diagnosis, risk factors, and outcome of urethral recurrences following radical cystectomy for bladder cancer in 729 male patients. Eur Urol (2007) 0.81
Laparoscopic management of spontaneous retroperitoneal hemorrhage. Urol Int (2011) 0.81
Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology (2008) 0.80
Laparoscopic live donor nephrectomy with the use of 3-mm instruments and laparoscope: initial experience at a tertiary center. Eur Urol (2011) 0.80
[Lithiasis in complete ureteral duplication and prostate cancer: combined surgery treatment]. Arch Ital Urol Androl (2003) 0.80
[Early ultrasound detection of renal tumors in patients with end stage renal disease in dialysis]. Arch Esp Urol (2007) 0.80
Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer. Curr Opin Urol (2012) 0.80
[The presence of a prolene mesh in the vagina]. Arch Esp Urol (2006) 0.80
Dietary olive oil and corn oil differentially affect experimental breast cancer through distinct modulation of the p21Ras signaling and the proliferation-apoptosis balance. Carcinogenesis (2009) 0.80
Disseminated retroperitoneal choriocarcinoma with open fistula to intestine. "Restitutio ad integrum" with chemotherapy alone. Clin Transl Oncol (2006) 0.79
Management of urethral recurrence in patients with Studer ileal neobladder. Eur Urol (2003) 0.79
Is bladder cycling useful in the urodynamic evaluation previous to renal transplantation? Urol Int (2005) 0.78
The road to real zero ischemia for partial nephrectomy. J Endourol (2013) 0.78
Clinical predictive factors of poor outcome in patients with stage pT0 disease at radical cystectomy. J Urol (2011) 0.78
[Vesico-ureteral reflux, endoscopic management]. Arch Argent Pediatr (2013) 0.77
Differential expression of H19 and vitamin D3 upregulated protein 1 as a mechanism of the modulatory effects of high virgin olive oil and high corn oil diets on experimental mammary tumours. Eur J Cancer Prev (2009) 0.76
Incidence of contralateral germ cell testicular tumors in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature. J Urol (2004) 0.76